熱門資訊> 正文

吉利德的Trodelvy获得了新的乳腺癌适应症

2026-06-25 04:37

The US FDA has approved Gilead Sciences' (GILD) Trodelvy (sacituzumab govitecan) as a first-line treatment as monotherapy and in combination with Merck's (MRK) Keytruda (pembrolizumab) for triple-negative breast cancer.
The monotherapy indication was granted based on results from the ASCENT-03 trial, while the combo indication saw support from ASCENT-04/KEYNOTE D-19.
Trodelvy is also approved for HR+/HER- metastatic breast cancer.

More on Gilead Sciences

Gilead Sciences: The Market Is Underestimating Its Growth Runway
Gilead Sciences, Inc. (GILD) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Gilead: 'Hold' On Biktarvy Sales Growth And MM Drug Development Program
Gilead weekly Yeztugo HIV pill sNDA accepted by FDA
Merck, Gilead share positive phase 3 results from combination HIV pill

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。